Comparative Pharmacology
Head-to-head clinical analysis: BREATHTEK UBT FOR H PYLORI versus R GENE 10.
Head-to-head clinical analysis: BREATHTEK UBT FOR H PYLORI versus R GENE 10.
BREATHTEK UBT FOR H-PYLORI vs R-GENE 10
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BREATHTEK UBT is a 13C-urea breath test that detects Helicobacter pylori infection. The patient ingests 13C-labeled urea; if H. pylori is present, its urease enzyme hydrolyzes urea to 13CO2, which is absorbed and exhaled, allowing detection by mass spectrometry or infrared spectroscopy.
Arginine is a semi-essential amino acid that serves as a substrate for nitric oxide (NO) synthesis via nitric oxide synthase (NOS), leading to vasodilation. It also stimulates growth hormone release and is involved in the urea cycle for ammonia detoxification.
75 mg of 13C-urea oral powder dissolved in 75 mL water, administered once after a baseline breath sample; a second breath sample is collected 30 minutes after dosing.
10 mg intravenously over 1-2 minutes, once daily for 5 days, repeat course after 2-3 weeks if needed.
None Documented
None Documented
13C-urea has a plasma half-life of approximately 0.5–1 hour. The 13CO2 exhaled peak occurs at 20–30 minutes, reflecting rapid urease hydrolysis. The terminal half-life is not clinically relevant as the breath test relies on early exhalation kinetics.
Terminal elimination half-life is 2-4 hours (mean 3 hours) in adults with normal renal function; prolonged to 8-18 hours in renal impairment.
BreathTek UBT (13C-urea) is metabolized by H. pylori urease to 13CO2, which is exhaled. Unmetabolized urea is renally excreted; renal elimination of unchanged 13C-urea accounts for approximately 20-30% of the administered dose, with the remainder exhaled as 13CO2 within 60 minutes. Fecal/biliary excretion is negligible.
Primarily renal (approximately 80-90% unchanged). Biliary/fecal elimination accounts for <5%.
Category C
Category C
Diagnostic Agent
Diagnostic Agent